anticoagulant

Blood clotting is like a chain of dominoes: one factor activates the next, and at the end a mesh forms to seal a wound. That is lifesaving after an injury but dangerous if a clot forms inside a vessel. An anticoagulant slows or removes one of the dominoes, so clots form less readily.

Mechanistically the clotting cascade is a series of proteases (clotting factors) that activate each other in turn. Different anticoagulants intervene at different points: warfarin lowers the body's supply of several factors by blocking vitamin K recycling; heparin supercharges the natural inhibitor antithrombin; and the direct oral anticoagulants are small molecules that bind one specific factor's active site.

The newer direct agents are a triumph of structure-based design. Direct thrombin inhibitors such as dabigatran and direct factor Xa inhibitors such as rivaroxaban and apixaban (note the shared 'xaban' fragment) were designed to slot precisely into the active site of a single clotting protease, giving more predictable effects than warfarin.

An honest caveat: every anticoagulant walks a tightrope, too little and clots form, too much and bleeding occurs, so the therapeutic window is narrow and, for some agents, dosing or monitoring must be carefully managed.